Combination therapy for dyslipidemia: safety and regulatory considerations.
Combination therapy for dyslipidemia: safety and regulatory considerations.
复制标题
血脂异常的联合治疗：安全性和监管考虑。
DOI：
10.1016/s0002-9149(02)02970-3
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
M. Davidson
中科院分区：
文献类型：
--
作者：
M. Davidson
联合治疗是治疗冠心病（CAD）患者血脂异常的有效方法。然而，联合治疗并不是CAD治疗中常用的策略。积极的血脂改变治疗通常需要使用联合治疗，包括他汀类药物联合烟酸、纤维酸衍生物、依折麦布或胆汁酸树脂。然而，他汀类药物与其他降脂药物联合使用的安全性问题以及患者对联合治疗的接受程度影响了他汀类药物在冠心病治疗中的应用。本文讨论了使用联合治疗血脂异常的几个安全性和监管方面的考虑。
The use of combination therapy is an effective way to manage dyslipidemia in patients with coronary artery disease (CAD). However, combination therapy is not a frequently used strategy in the treatment of CAD. Aggressive lipid-altering therapy often requires the use of combination therapy involving statins in conjunction with niacin, fibric-acid derivatives, ezetimibe, or bile acid resins. Yet, safety concerns regarding the combination of statins with other lipid-altering drugs and patient acceptance of combination therapy have influenced its application in the treatment of CAD. This article discusses several safety and regulatory considerations for the use of combination therapy for dyslipidemia.